Moderna Vaccine - Product Scorecard

Company: Moderna

Type: Covid-19 Vaccine
Product (brand name): mRNA-1273 (SpikeVax)
0%
compliance
with criteria
Share this score on social:

Other company scores

Bharat Biotech Vaccine
0%
Brii BioSciences Therapeutic
0%
CanSino Vaccine
0%
Celltrion Therapeutic
0%
CIGB Vaccine
0%
Texas Children’s Hospital Vaccine
0%
Finlay Vaccine
0%
Gamaleya Vaccine
0%
Gilead Therapeutic
0%
Johnson & Johnson Vaccine
0%
Moderna Vaccine
0%
Vaxine Vaccine
0%
Vektor Vaccine
0%
Zydus Vaccine
0%
AstraZeneca Antibody
0%
AstraZeneca Vaccine
0%
Eli Lilly Therapeutic 3
0%
Eli Lilly Therapeutic 2
0%
Eli Lilly Therapeutic 1
0%
MSD Therapeutic
0%
Novavax Vaccine
0%
Pfizer Therapeutic
0%
Pfizer Vaccine
0%
Regeneron Therapeutic
0%
Roche Therapeutic
0%
Sanofi Vaccine
0%
Sinopharm Vaccine
0%
Sinovac Vaccine
0%
GSK Therapeutic
0%
Explore the results of PAF’s research into the behaviour of Moderna . Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading).

Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.

Category A: Commitments and Accountability

The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.

The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.

A1: Does Moderna publish a global access plan for its product?

Moderna has a five-pillar strategy to ensure that low-income countries get access to its vaccine, including: not enforcing patents, supporting the Covax facility, facilitating donations by countries that bought more doses than they need, building an mRNA facility in Africa, and delivering between 2 to 3 billion doses to low-income countries in 2022.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
A2: Does Moderna commit to comply with human rights standards in relation to product development and marketing?

Moderna has a human rights policy which does not mention compliance with UN Guiding Principles on Business and Human Rights.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category C: International cooperation

The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.

C1: Does Moderna commit to C-TAP or MPP?

Moderna has not shown evidence of supporting a responsible licensing mechanism such as C-TAP or the MPP.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C2: Does Moderna commit to not enforcing the exclusive rights of Covid-19 related patents?

In October 2020, Moderna vowed not to enforce its patent rights during the pandemic and that it would be willing to license them to others after the pandemic.

On 08 February 2022, Moderna updated this pledge, stating that it will “never enforce its patents for COVID-19 vaccines against manufacturers in or for the 92 low- and middle-income countries in the Gavi COVAX Advance Market Commitment (AMC), provided that the manufactured vaccines are solely for use in the AMC 92 countries.” This is a narrower version of Moderna’s previous pledge,

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C3: Does Moderna supply to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator?

Moderna has donated 650 000 000 doses through COVAX.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C4: Does Moderna agree to license its Covid-19 medical products to other companies?

Moderna has established multiple fill-and-finish and distribution sites: Cipla (India), Rovi Pharma (Nigeria), Thermo-fisher, Samsung Biologics.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category E: Equality, non-discrimination & equity

The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.

E1: Does Moderna make the active ingredient available on reasonable grounds? [Only for therapeutics]

[Only applies to therapeutics]

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
E2: Does Moderna commit to full technology transfer to other manufacturers?

Moderna does not commit to full technology transfer to other manufacturers.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
E3: Does Moderna commit to non-profit, ‘fair’, or differential pricing?

Moderna states that it will make profit from the vaccine. There are different prices for the vaccine but those paid by middle-income countries and low-income countries are sometimes more than what is paid by high-income countries (Botswana, eg, payed 28,88 US dollars and the EU paid 25,50). The different prices cannot therefore be considered as part of a differential pricing policy based on ability to pay.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine